These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25325220)

  • 1. Management of type 2 diabetes mellitus in chronic kidney disease.
    Maffioli P; Derosa G
    Curr Med Res Opin; 2015 Jan; 31(1):95-7. PubMed ID: 25325220
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antidiabetic Drugs and the Kidney].
    Candido R
    G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960013
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.
    Mikhail N
    Postgrad Med; 2012 Jul; 124(4):138-44. PubMed ID: 22913902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):529-50. PubMed ID: 23461781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment.
    Mikov M; Pavlović N; Stanimirov B; Đanić M; Goločorbin-Kon S; Stankov K; Al-Salami H
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):1-14. PubMed ID: 31385198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes.
    Fadini GP; Bonora BM; Cappellari R; Menegazzo L; Vedovato M; Iori E; Marescotti MC; Albiero M; Avogaro A
    J Clin Endocrinol Metab; 2016 Feb; 101(2):748-56. PubMed ID: 26695864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
    Barnett AH
    Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DPP IV inhibitors: successes, failures and future prospects.
    Kshirsagar AD; Aggarwal AS; Harle UN; Deshpande AD
    Diabetes Metab Syndr; 2011; 5(2):105-12. PubMed ID: 22813415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Newer anti - diabetic therapies and chronic kidney disease].
    Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
    G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
    Barnett AH
    Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease.
    Kamiya H
    Hemodial Int; 2017 Jan; 21(1):72-83. PubMed ID: 27436163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Expert Opin Investig Drugs; 2010 Jan; 19(1):133-40. PubMed ID: 19947894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [How I TREAT ... THE ROLE OF DPP-4 INHIBITORS (GLIPTINS) IN THE TREATMENT OF TYPE 2 DIABETES].
    Scheen AJ
    Rev Med Liege; 2015 Dec; 70(12):593-9. PubMed ID: 26867302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations.
    Ceriello A; Inagaki N
    J Diabetes Investig; 2017 Jan; 8(1):19-28. PubMed ID: 27180612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
    Groop PH; Cooper ME; Perkovic V; Sharma K; Schernthaner G; Haneda M; Hocher B; Gordat M; Cescutti J; Woerle HJ; von Eynatten M
    Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MARLINA-T2D trial: putting the results into clinical perspective.
    Lajara R
    Expert Rev Endocrinol Metab; 2018 May; 13(3):173-176. PubMed ID: 30058901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
    Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.